CommercialPrior AuthMedium impact
08.01.52g, Mogamulizumab-kpkc (Poteligeo®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jul 1, 2025
We identified it
Jun 19, 2026
Summary
Policy 08.01.52g establishes new medical necessity criteria for Mogamulizumab-kpkc (Poteligeo®), a specialty pharmacy medication. The billing team must implement updated prior authorization requirements and documentation standards effective immediately to ensure claim approval and avoid denials.
Action Required
By July 1, 2025: Billing team must update prior authorization workflows in billing software to reflect new medical necessity criteria for Mogamulizumab-kpkc (J9204). Coordinate with providers and pharmacy to ensure all claims include required medical necessity documentation before submission. Update claim submission templates and prior auth request forms to capture criteria outlined in policy 08.01.52g. Flag all claims for J9204 for manual review if documentation is incomplete. Failure to submit complete medical necessity documentation will result in claim denials.